Abstract: Provided herein are osteogenic placental adherent cells (OPACs), methods of using OPACs and OPAC populations, and methods of culturing, proliferating, expanding, or differentiating the OPACs. Further provided herein are methods of using the OPACs to formulate implantable or injectable compositions suitable for administration to a subject. Still further provided herein are provides methods for treating bone defects with OPACs and compositions comprising OPACs. Also provided herein are methods of using OPACs in the treatment and management of multiple myeloma, e.g., reducing the progression of, halting the progression of, or improving, one or more symptoms of multiple myeloma in an individual having multiple myeloma, comprising administering a plurality of OPACs to the individual.
Type:
Application
Filed:
February 2, 2016
Publication date:
June 2, 2016
Applicant:
ANTHROGENESIS CORPORATION
Inventors:
Sascha D. Abramson, Marian Guelakis, Mohammad A. Heidaran, Kristen Labazzo, Shmuel Yaccoby
Abstract: Provided herein are methods of using adherent placental stem cells and placental stem cell populations, and methods of culturing, proliferating and expanding the same. Also provided herein are methods of differentiating the placental stem cells. Further provided herein are methods of using the placental stem cells to formulate implantable or injectable compositions suitable for administration to a subject. Still further provided herein are provides methods for treating bone defects with stem cells and compositions comprising stem cells.
Type:
Grant
Filed:
September 16, 2013
Date of Patent:
May 17, 2016
Assignee:
Anthrogenesis Corporation
Inventors:
James W. Edinger, Robert J. Hariri, Jia-Lun Wang, Qian Ye, Kristen S. Labazzo, Marian Pereira, Sascha Dawn Abramson
Abstract: The present invention provides placental stem cells and placental stem cell populations, and methods of culturing, proliferating and expanding the same. The invention also provides methods of differentiating the placental stem cells. The invention further provides methods of using the placental stem cells in assays and for transplanting.
Type:
Application
Filed:
June 10, 2015
Publication date:
May 12, 2016
Applicant:
ANTHROGENESIS CORPORATION
Inventors:
James Edinger, Qian Ye, Jai-Lun Wang, Robert Hariri
Abstract: Provided herein are methods of treating individuals having diseases or disorders of the circulatory system, using placental cells, e.g., the placental stem cells and placental multipotent cells (PDACs) described herein, and populations of such placental cells. The invention also provides methods of angiogenesis using such cells or populations of cells comprising such cells.
Type:
Application
Filed:
December 22, 2015
Publication date:
April 21, 2016
Applicant:
ANTHROGENESIS CORPORATION
Inventors:
Stewart Abbot, James W. Edinger, Aleksandar Francki, Robert J. Hariri, Vladimir Jankovic, Aleksandr Kaplunovsky, Kristen Labazzo, Eric Law, Neerav D. Padliya, Jennifer Paredes, Jia-Lun Wang
Abstract: Provided herein are methods of treatment of an individual having pain, e.g., neuropathic pain, comprising administering to the individual a therapeutically effective amount of tissue culture plastic adherent placental stem cells (PDAC™).
Abstract: Provided herein are methods of treating individuals having diseases or disorders of the circulatory system, using placental cells, e.g., the placental stem cells and placental multipotent cells (PDACs) described herein, and populations of such placental cells. The invention also provides methods of angiogenesis using such cells or populations of cells comprising such cells.
Type:
Grant
Filed:
April 6, 2011
Date of Patent:
February 9, 2016
Assignee:
ANTHROGENESIS CORPORATION
Inventors:
Stewart Abbot, James W. Edinger, Aleksandar Francki, Robert J. Hariri, Vladimir Jankovic, Aleksandr Kaplunovsky, Kristen Labazzo, Eric Law, Neerav D. Padliya, Jennifer Paredes, Jia-Lun Wang
Abstract: Provided herein are methods of producing erythrocytes from hematopoietic cells, particularly hematopoietic cells from placental perfusate in combination with hematopoietic cells from umbilical cord blood, wherein the method results in accelerated expansion and differentiation of the hematopoietic cells to more efficiently produce administrable erythrocytes. Further provided herein is a bioreactor in which hematopoietic cell expansion and differentiation takes place.
Type:
Grant
Filed:
October 11, 2013
Date of Patent:
February 9, 2016
Assignee:
Anthrogenesis Corporation
Inventors:
Stewart Abbot, Lin Kang, Vanessa Voskinarian-Berse, Xiaokui Zhang
Abstract: Provided herein are methods of producing extracellular matrix (ECM) that are superior to previously-described methods. Extracellular matrix (ECM) comprises protein that forms many structures in the body including tendons, ligaments, and sheets that support skin and internal organs. There remains a need in the art for ECM compositions that have improved cell attachment characteristics and methods of making such ECM compositions.
Type:
Application
Filed:
March 14, 2014
Publication date:
February 4, 2016
Applicant:
ANTHROGENESIS CORPORATION
Inventors:
Mohit B. Bhatia, Aleksandr Kaplunovsky, Xuan Guo
Abstract: Provided herein are cells, e.g., T cells expressing artificial cell death polypeptides that cause death of a cell, e.g., cells (e.g., T lymphocytes) expressing the cell death polypeptide, when the cell death polypeptide is multimerized or dimerized. Also provided herein is use of such cells, e.g., T lymphocytes, to treat diseases such as cancer.
Type:
Application
Filed:
March 14, 2014
Publication date:
February 4, 2016
Applicant:
ANTHROGENESIS CORPORATION
Inventors:
Stewart Abbot, Tianjian Li, Bitao Liang
Abstract: Provided herein are placental stem cells that exhibit increased survival (“enhanced placental stem cells”), compositions comprising such placental stem cells, and methods of using such placental stem cells and compositions.
Type:
Application
Filed:
March 13, 2014
Publication date:
January 21, 2016
Applicant:
ANTHROGENESIS CORPORATION
Inventors:
Stewart Abbot, Kathy Karasiewicz-Mendez, Xiaokui Zhang
Abstract: Provided herein are placental perfusate, placental perfusate cells, and placenta-derived intermediate natural killer cells, and combinations thereof. Also provided herein are compositions comprising the same, and methods of using placental perfusate, placental perfusate cells, and placenta-derived intermediate natural killer cells, and combinations thereof, to suppress the growth or proliferation of tumor cells, cancer cells, and the like, and to treat individuals having tumor cells.
Type:
Grant
Filed:
August 13, 2012
Date of Patent:
December 22, 2015
Assignee:
Anthrogenesis Corporation
Inventors:
Robert J. Hariri, Mohammad A. Heidaran, Lin Kang, Neerav Dilip Padliya, Ajai Pal, Vanessa Voskinarian-Berse, Andrew Zeitlin, Xiaokui Zhang
Abstract: Provided herein are methods of producing erythrocytes from hematopoietic cells, particularly hematopoietic cells from placental perfusate in combination with hematopoietic cells from umbilical cord blood, wherein the method results in accelerated expansion and differentiation of the hematopoietic cells to more efficiently produce administrable erythrocytes. Further provided herein is a bioreactor in which hematopoietic cell expansion and differentiation takes place.
Type:
Grant
Filed:
August 6, 2008
Date of Patent:
December 1, 2015
Assignee:
Anthrogenesis Corporation
Inventors:
Mohammad A. Heidaran, Xiaokui Zhang, Lin Kang, Andrew Zeitlin, Vanessa R. Voskinarian-Berse, Stewart Ernest Abbott
Abstract: Provided herein are uses of compositions comprising extracellular matrix (ECM) and compositions comprising ECM components in the treatment of non-dental oral lesions.
Type:
Application
Filed:
December 6, 2013
Publication date:
November 5, 2015
Applicant:
ANTHROGENESIS CORPORATION
Inventors:
Robert J. Hariri, Jodi P. Gurney, Mohit B. Bhatia, Wolfgang Hofgartner
Abstract: Provided herein are methods of suppression of proliferation and growth of cells of bone-related cancers, e.g., multiple myeloma or chondrosarcoma cells, using placental cells, e.g., the placental stem cells described herein, and populations of such placental cells. Also provided herein are methods of treating individuals having cells of a bone-related cancer.
Type:
Application
Filed:
July 6, 2015
Publication date:
October 29, 2015
Applicant:
ANTHROGENESIS CORPORATION
Inventors:
Xiaokui Zhang, Shmuel Yaccoby, Sascha Abramson, Robert J. Hariri
Abstract: Anoikis resistant placental stem cells (arPSCs) with increased survival in low-attachment environments, and thus can advantageously be used, e.g., in therapies based on their ability to persist for longer durations of time in an unattached state. A method of modifying placental stem cells to make them anoikis resistant, comprising contacting the placental stem cells with an effective amount of modulatory RNA molecules, such that one or more genes associated with anoikis of the placental stem cells is inhibited. Further discloses are genes that are associated with anoikis for modulation.
Type:
Application
Filed:
December 13, 2013
Publication date:
October 29, 2015
Applicant:
ANTHROGENESIS CORPORATION
Inventors:
Xiaokui Zhang, Stewart Abbot, Vanessa Voskinarian-Berse
Abstract: Provided herein are therapeutic polypeptides, e.g., chimeric antigen receptors, able to direct an immune cell, e.g., a T lymphocyte to a target antigen, and able to cause the T cell to proliferate or to kill cells displaying the antigen when the antigen binds to the polypeptide, wherein the polypeptides comprise a transmembrane domain from a T cell co-inhibitory protein such as CTLA4 or PD-1. Also provided herein are T lymphocytes expressing the polypeptides, and use of such T lymphocytes to treat diseases such as cancer.
Type:
Application
Filed:
December 19, 2013
Publication date:
October 29, 2015
Applicant:
ANTHROGENESIS CORPORATION
Inventors:
Stewart Abbot, Bitao Liang, Tianjian Li
Abstract: The present invention provides compositions and methods of using placental stem cells that originate from a post-partum placenta with conventional cord blood compositions or other stem or progenitor cells. The placental stem cells can be used alone or in a mixture with other stem cell populations. In accordance with the present invention, the placental stem cells may be mixed with other stem cell populations, including but not limited to, umbilical cord blood, fetal and neonatal hematopoietic stem cells and progenitor cells, human stem cells and progenitor cells derived from bone marrow. The placental stem cells and the mixed populations of placental stem cells and stem cells have a multitude of uses and applications, including but not limited to, therapeutic uses for transplantation and treatment and prevention of disease, and diagnostic and research uses.
Abstract: The present invention provides a method of extracting and recovering embryonic-like stem cells, including, but not limited to pluripotent or multipotent stem cells, from an exsanguinated human placenta. A placenta is treated to remove residual umbilical cord blood by perfusing an exsanguinated placenta, preferably with an anticoagulant solution, to flush out residual cells. The residual cells and perfusion liquid from the exsanguinated placenta are collected, and the embryonic-like stem cells are separated from the residual cells and perfusion liquid. The invention also provides a method of utilizing the isolated and perfused placenta as a bioreactor in which to propagate endogenous cells, including, but not limited to, embryonic-like stem cells. The invention also provides methods for propagation of exogenous cells in a placental bioreactor and collecting the propagated exogenous cells and bioactive molecules therefrom.